Repair of pre-mRNA splicing: Prospects for a therapy for spinal muscular atrophy

RNA Biology

Volumn 7, Issue 4, 2010, Pages 430-440

  Nlend Nlend, Rachel ^a   Meyer, Kathrin ^a   Schümperli, Daniel ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antisense oligonucleotides; Bifunctional RNA; Exon definition; Gene therapy; Motoneurons; Splicing enhancer; U7snRNA

Indexed keywords

HYDROXYUREA; MESSENGER RNA; MESSENGER RNA PRECURSOR; POLYPYRIMIDINE TRACT BINDING PROTEIN; VALPROIC ACID;

CAUCASIAN; CENTRAL NERVOUS SYSTEM; CYSTIC FIBROSIS; EXON; GENE; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; GENETIC CODE; GENETIC TRANSCRIPTION; INFANT MORTALITY; KUGELBERG WELANDER DISEASE; LIFE EXPECTANCY; MUSCLE WEAKNESS; MYOTONIC DYSTROPHY; NONHUMAN; NUCLEOTIDE BINDING SITE; REVIEW; RNA ANALYSIS; RNA REPAIR; RNA SPLICING; SPINAL MUSCULAR ATROPHY; SPLICING DEFECT; SURVIVAL MOTOR NEURON 1 GENE; SURVIVAL MOTOR NEURON 2 GENE; WERDNIG HOFFMANN DISEASE;

EUKARYOTA; PRIMATES;

EID: 77957312146     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.7.4.12206     Document Type: Review

References (155)

1. Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431:931-45.
2. O'Donovan C, Apweiler R, Bairoch A. The human proteomics initiative (HPI). Trends in Biotechnology 2001; 19:178-81.
3. Matlin AJ, Clark F, Smith CWJ. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005; 6:386-98.
4. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40:1413-5.
5. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456:470-6. (Pubitemid 352759009)
6. Deutsch M, Long M. Intron-exon structures of eukaryotic model organisms. Nucl Acids Res 1999; 27:3219-28. (Pubitemid 29355739)
7. Burge CB, Tuschl T, Sharp PA. Splicing of precursors to mRNAs by the spliceosome in The RNA World (Gesteland RF, Cech TR, Atkins JF, eds) 525-560 (CSHL Press, Cold Spring Harbor NY, 1999).
8. Graveley BR, Maniatis T. Arginine/Serine-Rich Domains of SR Proteins Can Function as Activators of Pre-mRNA Splicing. Molecular Cell 1998; 1:765-71. (Pubitemid 128379254)
9. Blencowe BJ. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci 2000; 25:106-10.
10. Shepard P, Hertel K. The SR protein family. Genome Biology 2009; 10:242.
11. Pozzoli U, Sironi M. Silencers regulate both constitutive and alternative splicing events in mammals. Cellular and Molecular Life Sciences 2005; 62:1579-604. (Pubitemid 41021581)
12. Martinez-Contreras R, Cloutier P, Shkreta L, Fisette JF, Revil T, Chabot B. hnRNP proteins and splicing control. Adv Exp Med Biol 2007; 623:123-47.
13. Caceres JF, Kornblihtt AR. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends in Genetics 2002; 18:186-93.
14. Buratti E, Baralle FE. Influence of RNA Secondary Structure on the Pre-mRNA Splicing Process. Mol Cell Biol 2004; 24:10505-14. (Pubitemid 39603113)
15. Calarco JA, Superina S, O'Hanlon D, Gabut M, Raj B, Pan Q, et al. Regulation of Vertebrate Nervous System Alternative Splicing and Development by an SR-Related Protein. Cell 2009; 138:898-910.
16. Jin Y, Suzuki H, Maegawa S, Endo H, Sugano S, Hashimoto K, et al. A vertebrate RNA-binding protein Fox-1 regulates tissue-specific splicing via the pentanucleotide GCAUG. EMBO J 2003; 22:905-12. (Pubitemid 36227792)
17. Underwood JG, Boutz PL, Dougherty JD, Stoilov P, Black DL. Homologues of the Caenorhabditis elegans Fox-1 Protein Are Neuronal Splicing Regulators in Mammals. Mol Cell Biol 2005; 25:10005-16. (Pubitemid 41572747)
18. Kuroyanagi H. Fox-1 family of RNA-binding proteins. Cellular and Molecular Life Sciences 2009; 66:3895-907.
19. Makeyev EV, Zhang J, Carrasco MA, Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell 2007; 27:435-48. (Pubitemid 47126944)
20. Boutz PL, Stoilov P, Li Q, Lin CH, Chawla G, Ostrow K, et al. A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. Genes Dev 2007; 21:1636-52. (Pubitemid 47026368)
21. Coutinho-Mansfield GC, Xue Y, Zhang Y, Fu XD. PTB/nPTB switch: a post-transcriptional mechanism for programming neuronal differentiation. Genes Dev 2007; 21:1573-7. (Pubitemid 47026360)
22. Ule J, Ule A, Spencer J, Williams A, Hu JS, Cline M, et al. Nova regulates brain-specific splicing to shape the synapse. Nat Genet 2005; 37:844-52. (Pubitemid 41077110)
23. Ule J, Stefani G, Mele A, Ruggiu M, Wang X, Taneri B, et al. An RNA map predicting Nova-dependent splicing regulation. Nature 2006; 444:580-6. (Pubitemid 44864431)
24. Ule J, Darnell RB. RNA binding proteins and the regulation of neuronal synaptic plasticity. Current Opinion in Neurobiology 2006; 16:102-10. (Pubitemid 43221860)
25. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 1992; 90:41-54.
26. Krawczak M, Thomas NS, Hundrieser B, Mort M, Wittig M, Hampe J, et al. Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution and consequences for mRNA splicing. Hum Mutat 2007; 28:150-8.
27. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002; 3:285-98.
28. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 2007; 8:749-61.
29. Baralle D, Baralle M. Splicing in action: assessing disease causing sequence changes. J Med Genet 2005; 42:737-48.
30. Valcarcel J, Singh R, Zamore PD, Green MR. The protein Sex-lethal antagonizes the splicing factor U2AF to regulate alternative splicing of transformer pre-mRNA. Nature 1993; 362:171-5.
31. Dominski Z, Kole R. Cooperation of pre-mRNA sequence elements in splice site selection. Mol Cell Biol 1992; 12:2108-14.
32. Penalva LOF, Lallena MJ, Valcarcel J. Switch in 3′ Splice Site Recognition between Exon Definition and Splicing Catalysis Is Important for Sex-lethal Autoregulation. Mol Cell Biol 2001; 21:1986-96.
33. Buratti E, Muro AF, Giombi M, Gherbassi D, Iaconcig A, Baralle FE. RNA Folding Affects the Recruitment of SR Proteins by Mouse and Human Polypurinic Enhancer Elements in the Fibronectin EDA Exon. Mol Cell Biol 2004; 24:1387-400.
34. Warf MB, Diegel JV, von Hippel PH, Berglund JA. The protein factors MBNL1 and U2AF65 bind alternative RNA structures to regulate splicing. PNAS 2009; 106:9203-8.
35. Ward AJ, Cooper TA. The pathobiology of splicing. J Pathol 2010; 220:152-63.
36. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, et al. A Muscleblind Knockout Model for Myotonic Dystrophy. Science 2003; 302:1978-80.
37. Pearn J. Classification of spinal muscular atrophies. Lancet 1980; 1:919-22.
38. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000; 15:228-37.
39. Talbot K, Davies KE. Spinal muscular atrophy. Semin Neurol 2001; 21:189-97.
40. Briese M, Esmaeili B, Sattelle DB. Is spinal muscular atrophy the result of defects in motor neuron processes? Bioessays 2005; 27:946-57.
41. Lefebvre S, Burglen L, Frezal J, Munnich A, Melki J. The role of the SMN gene in proximal spinal muscular atrophy. Hum Mol Genet 1998; 7:1531-6.
42. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, et al. A mouse model for spinal muscular atrophy. Nat Genet 2000; 24:66-70.
43. Monani UR, Sendtner M, Coovert DD, Parsons DW, Andreassi C, Le TT, et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 2000; 9:333-9.
44. Monani UR. Spinal Muscular Atrophy: A Deficiency in a Ubiquitous Protein; a Motor Neuron-Specific Disease. Neuron 2005; 48:885-95.
45. Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO, Mendell JR, et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet 1997; 6:1205-14. (Pubitemid 27351059)
46. Briese M, Richter DU, Sattelle DB, Ulfig N. SMN, the product of the spinal muscular atrophy-determining gene, is expressed widely but selectively in the developing human forebrain. J Comp Neurol 2006; 497:808-16. (Pubitemid 43993444)
47. Liu Q, Fischer U, Wang F, Dreyfuss G. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 1997; 90:1013-21.
48. Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 1998; 95:615-24. (Pubitemid 28544123)
49. Meister G, Bühler D, Pillai R, Lottspeich F, Fischer U. A multiprotein complex mediates the ATP-dependent assembly of spliceosomal U snRNPs. Nat Cell Biol 2001; 3:945-9. (Pubitemid 34428738)
50. Meister G, Eggert C, Fischer U. SMN-mediated assembly of RNPs: a complex story. Trends Cell Biol 2002; 12:472-8. (Pubitemid 35346518)
51. Paushkin S, Gubitz AK, Massenet S, Dreyfuss G. The SMN complex, an assemblyosome of ribonucleoproteins. Curr Opin Cell Biol 2002; 14:305-12.
52. Pillai RS, Grimmler M, Meister G, Will CL, Lührmann R, Fischer U, Schümperli D. Unique Sm core structure of U7 snRNPs: assembly by a specialized SMN complex and the role of a new component, Lsm11, in histone RNA processing. Genes Dev 2003; 17:2321-33. (Pubitemid 37128646)
53. Hebert MD, Szymczyk PW, Shpargel KB, Matera AG. Coilin forms the bridge between Cajal bodies and SMN, the spinal muscular atrophy protein. Genes Dev 2001; 15:2720-9.
54. Matera AG, Shpargel KB. Pumping RNA: nuclear bodybuilding along the RNP pipeline. Current Opinion in Cell Biology 2006; 18:317-24.
55. Narayanan U, Ospina JK, Frey MR, Hebert MD, Matera AG. SMN, the spinal muscular atrophy protein, forms a pre-import snRNP complex with snurportin1 and importin beta. Hum Mol Genet 2002; 11:1785-95. (Pubitemid 34812099)
56. Huber J, Cronshagen U, Kadokura M, Marshallsay C, Wada T, Sekine M, et al. Snurportin1, an m3G-capspecific nuclear import receptor with a novel domain structure. EMBO J 1998; 17:4114-26. (Pubitemid 28333995)
57. Terns MP, Terns RM. Macromolecular complexes: SMN - the master assembler. Curr Biol 2001; 11:862-4.
58. Gabanella F, Butchbach MER, Saieva L, Carissimi C, Burghes AHM, Pellizzoni L. Ribonucleoprotein Assembly Defects Correlate with Spinal Muscular Atrophy Severity and Preferentially Affect a Subset of Spliceosomal snRNPs. PLoS ONE 2007; 2:921.
59. Zhang Z, Lotti F, Dittmar K, Younis I, Wan L, Kasim M, Dreyfuss G. SMN Deficiency Causes Tissue-Specific Perturbations in the Repertoire of snRNAs and Widespread Defects in Splicing. Cell 2008; 133:585-600.
60. Chari A, Paknia E, Fischer U. The role of RNP biogenesis in spinal muscular atrophy. Curr Opin Cell Biol 2009; 21:387-93.
61. Fuller HR, Man NT, Lam LT, Thanh LT, Keough RA, Asperger A, et al. The SMN Interactome Includes Myb-Binding Protein 1a. Journal of Proteome Research 2009; 9:556-63.
62. Rossoll W, Jablonka S, Andreassi C, Kroning AK, Karle K, Monani UR, et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol 2003; 163:801-12.
63. Carrel TL, McWhorter ML, Workman E, Zhang H, Wolstencroft EC, Lorson C, et al. Survival motor neuron function in motor axons is independent of functions required for small nuclear ribonucleoprotein biogenesis. J Neurosci 2006; 26:11014-22.
64. Fan L, Simard LR. Survival motor neuron (SMN) protein: role in neurite outgrowth and neuromuscular maturation during neuronal differentiation and development. Hum Mol Genet 2002; 11:1605-14.
65. Sharma A, Lambrechts A, Hao Lt, Le TT, Sewry CA, Ampe C, et al. A role for complexes of survival of motor neurons (SMN) protein with gemins and profilin in neurite-like cytoplasmic extensions of cultured nerve cells. Exp Cell Res 2005; 309:185-97. (Pubitemid 41191234)
66. Rossoll W, Kroning AK, Ohndorf UM, Steegborn C, Jablonka S, Sendtner M. Specific interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in motor axons? Hum Mol Genet 2002; 11:93-105.
67. Giesemann T, Rathke-Hartlieb S, Rothkegel M, Bartsch JW, Buchmeier S, Jockusch BM, et al. A Role for Polyproline Motifs in the Spinal Muscular Atrophy Protein SMN. J Biol Chem 1999; 274:37908-14.
68. Piazzon N, Rage F, Schlotter F, Moine H, Branlant C, Massenet S. In vitro and in cellulo evidences for association of the survival of motor neuron complex with the fragile X mental retardation protein. J Biol Chem 2008; 283:5598-610.
69. Cifuentes-Diaz C, Nicole S, Velasco ME, Borra- Cebrian C, Panozzo C, Frugier T, et al. Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. Hum Mol Genet 2002; 11:1439-47.
70. Jablonka S, Wiese S, Sendtner M. Axonal defects in mouse models of motoneuron disease. Journal of Neurobiology 2004; 58:272-86. (Pubitemid 38173724)
71. Murray LM, Comley LH, Thomson D, Parkinson N, Talbot K, Gillingwater TH. Selective vulnerability of motor neurons and dissociation of pre- and postsynaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet 2008; 17:949-62. (Pubitemid 351426029)
72. Kariya S, Park GH, Maeno-Hikichi Y, Leykekhman O, Lutz C, Arkovitz MS, et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet 2008; 17:2552-69.
73. McGovern VL, Gavrilina TO, Beattie CE, Burghes AHM. Embryonic motor axon development in the severe SMA mouse. Hum Mol Genet 2008; 17:2900-9.
74. Kong LL, Wang XY, Choe DW, Polley M, Burnett BG, Bosch-Marce M, et al. Impaired Synaptic Vesicle Release and Immaturity of Neuromuscular Junctions in Spinal Muscular Atrophy Mice. J Neurosci 2009; 29:842-51.
75. Murray LM, Lee S, Baumer D, Parson SH, Talbot K, Gillingwater TH. Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy. Hum Mol Genet 2009; 506.
76. Voigt T, Meyer K, Baum O, Schumperli D. Ultrastructural changes in diaphragm neuromuscular junctions in a severe mouse model for Spinal Muscular Atrophy: Phenotypic rescue by bifunctional U7 snRNA correcting SMN2 splicing. Neuromuscul Disord 2010; In press.
77. Burghes AHM, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci 2009; 10:597-609.
78. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999; 96:6307-11. (Pubitemid 29256661)
79. Le TT, Pham LT, Butchbach ME, Zhang HL, Monani UR, Coovert DD, et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 2005; 14:845-57.
80. Lorson CL, Strasswimmer J, Yao JM, Baleja JD, Hahnen E, Wirth B, et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet 1998; 19:63-6. (Pubitemid 28242025)
81. Lorson CL, Androphy EJ. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 2000; 9:259-65.
82. Hofmann Y, Lorson CL, Stamm S, Androphy EJ, Wirth B. Htra2-beta1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci USA 2000; 97:9618-23. (Pubitemid 30650825)
83. Young PJ, DiDonato CJ, Hu D, Kothary R, Androphy EJ, Lorson CL. SRp30c-dependent stimulation of survival motor neuron (SMN) exon 7 inclusion is facilitated by a direct interaction with hTra2{beta}1. Hum Mol Genet 2002; 11:577-87.
84. Hofmann Y, Wirth B. hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1. Hum Mol Genet 2002; 11:2037-49. (Pubitemid 34919278)
85. Cartegni L, Krainer AR. Disruption of an SF2/ASFdependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 2002; 30:377-84.
86. Cartegni L, Hastings ML, Calarco JA, de Stanchina E, Krainer AR. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet 2006; 78:63-77. (Pubitemid 41833160)
87. Kashima T, Manley JL. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet 2003; 34:460-3. (Pubitemid 36935342)
88. Kashima T, Rao N, David CJ, Manley JL. hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. Hum Mol Genet 2007; 16:3149-59. (Pubitemid 350131332)
89. Miyajima H, Miyaso H, Okumura M, Kurisu J, Imaizumi K. Identification of a cis-acting element for the regulation of SMN exon 7 splicing. J Biol Chem 2002; 277:23271-7. (Pubitemid 34952155)
90. Singh NK, Singh NN, Androphy EJ, Singh RN. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 2006; 26:1333-46.
91. Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR. Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice. American Journal of Human Genetics 2008; 82:834-48.
92. Gladman J, Chandler D. Intron 7 conserved sequence elements regulate the splicing of the SMN genes. Human Genetics 2009; 126:833-41.
93. Goren A, Ram O, Amit M, Keren H, Lev-Maor G, Vig I, et al. Comparative Analysis Identifies Exonic Splicing Regulatory Sequences - The Complex Definition of Enhancers and Silencers. Molecular Cell 2006; 22:769-81. (Pubitemid 43912467)
94. Singh NN, Androphy EJ, Singh RN. In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes. RNA 2004; 10:1291-305.
95. Singh NN, Singh RN, Androphy EJ. Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes. Nucleic Acids Res 2007; 35:371-89.
96. Marquis J, Meyer K, Angehrn L, Kämpfer SS, Rothen-Rutishauser B, Schümperli D. Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. Mol Ther 2007; 15:1479-86. (Pubitemid 47099305)
97. Scholl R, Marquis J, Meyer K, Schümperli D. Spinal Muscular Atrophy: position and functional importance of the branch site preceding SMN exon 7. RNA Biol 2007; 4:34-7.
98. Gennarelli M, Lucarelli M, Capon F, Pizzuti A, Merlini L, Angelini C, et al. Survival Motor-Neuron Gene Transcript Analysis in Muscles from Spinal Muscular-Atrophy Patients. Biochem Biophys Res Commun 1995; 213:342-8.
99. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80:155-65.
100. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003; 12:2481-9.
101. Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, Coovert DD, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003; 54:647-54.
102. Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson SL, et al. Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy. PLoS ONE 2009; 4:5268.
103. Andreassi C, Angelozzi C, Tiziano FD, Vitali T, De Vincenzi E, Boninsegna A, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2003; 12:59-65.
104. Mercuri E, Bertini E, Messina S, Solari A, D'Amico A, Angelozzi C, et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007; 68:51-5.
105. Grzeschik SM, Ganta M, Prior TW, Heavlin WD, Wang CH. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 2005; 58:194-202. (Pubitemid 41098877)
106. Liang WC, Yuo CY, Chang JG, Chen YC, Chang YF, Wang HY, et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. J Neurol Sci 2008; 268:87-94.
107. Butchbach MER, Singh J, Thorsteinsdottir M, Saieva L, Slominski E, Thurmond J, et al. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet 2010; 19:454-67.
108. Mattis V, Rai R, Wang J, Chang CW, Coady T, Lorson C. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Human Genetics 2006; 120:589-601. (Pubitemid 44669792)
109. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotech 2010; 28:271-4.
110. Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010; 120:1253-64.
111. Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Ronchi D, et al. Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. J Clin Invest 2008; 118:3316-30.
112. Soret J, Bakkour N, Maire S, Durand S, Zekri L, Gabut M, et al. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. PNAS 2005; 102:8764-9. (Pubitemid 40862809)
113. Tazi J, Bakkour N, Soret J, Zekri L, Hazra B, Laine W, et al. Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diospyrin derivatives. Mol Pharmacol 2005; 67:1186-94. (Pubitemid 40410418)
114. Andreassi C, Jarecki J, Zhou J, Coovert DD, Monani UR, Chen X, et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001; 10:2841-9. (Pubitemid 34026465)
115. Hastings ML, Berniac J, Liu YH, Abato P, Jodelka FM, Barthel L, et al. Tetracyclines That Promote SMN2 Exon 7 Splicing as Therapeutics for Spinal Muscular Atrophy. Sci Transl Med 2009; 1:5-12.
116. Vacek M, Sazani P, Kole R. Antisense-mediated redirection of mRNA splicing. Cell Mol Life Sci 2003; 60:825-33.
117. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003; 270:1628-44.
118. Aartsma-Rus A, van Ommen GJ. Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. RNA 2007; 13:1609-24. (Pubitemid 47481669)
119. Lim SR, Hertel KJ. Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing. J Biol Chem 2001; 276:45476-83.
120. Singh NN, Shishimorova M, Cao LC, Gangwani L, Singh RN. A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol 2009; 6:341-50.
121. Williams JH, Schray RC, Patterson CA, Ayitey SO, Tallent MK, Lutz GJ. Oligonucleotide-Mediated Survival of Motor Neuron Protein Expression in CNS Improves Phenotype in a Mouse Model of Spinal Muscular Atrophy. J Neurosci 2009; 29:7633-8.
122. Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR. Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon. PLoS Biol 2007; 5:73.
123. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003; 10:120-5. (Pubitemid 36177092)
124. Skordis LA, Dunckley MG, Yue B, Eperon IC, Muntoni F. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA 2003; 100:4114-9. (Pubitemid 36418166)
125. Dickson A, Osman E, Lorson C. A Negatively-Acting Bifunctional RNA Increases Survival Motor Neuron in vitro and in vivo. Hum Gene Ther 2008.
126. Baughan TD, Dickson A, Osman EY, Lorson CL. Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum Mol Genet 2009; 18:1600-11.
127. Gorman L, Schümperli D, Kole R. Alteration of premRNA splicing patterns by modified small nuclear RNAs in Progress in Gene Therapy - basic and clinical frontiers (Bertolotti R, Parvez SH, Nagatsu T, eds) 455-473 (VSP BV, Utrecht, The Netherlands, 2000).
128. Asparuhova M, Kole R, Schümperli D. Antisense derivatives of U7 and other small nuclear RNAs as tools to modify pre-mRNA splicing patterns. Gene Therapy Regul 2004; 2:321-49. (Pubitemid 40909343)
129. Müller B, Schümperli D. The U7 snRNP and the hairpin binding protein: Key players in histone mRNA metabolism. Semin Cell Dev Biol 1997; 8:567-76. (Pubitemid 127348654)
130. Schümperli D, Pillai RS. The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein. Cell Mol Life Sci 2004; 60:2560-70. (Pubitemid 39586517)
131. Grimm C, Stefanovic B, Schümperli D. The low abundance of U7 snRNA is partly determined by its Sm binding site. EMBO J 1993; 12:1229-38. (Pubitemid 23095872)
132. Stefanovic B, Hackl W, Lührmann R, Schümperli D. Assembly, nuclear import and function of U7 snRNPs studied by microinjection of synthetic U7 RNA into Xenopus oocytes. Nucl Acids Res 1995; 23:3141-51.
133. Pillai RS, Will CL, Lührmann R, Schümperli D, Müller B. Purified U7 snRNPs lack the Sm proteins D1 and D2 but contain Lsm10, a new 14 kDa Sm D1-like protein. EMBO J 2001; 20:5470-9. (Pubitemid 32959467)
134. Gorman L, Suter D, Emerick V, Schümperli D, Kole R. Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci USA 1998; 95:4929-34. (Pubitemid 28208527)
135. Suter D, Tomasini R, Reber U, Gorman L, Kole R, Schümperli D. Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human beta-thalassemic mutations. Hum Mol Genet 1999; 8:2415-23.
136. Lacerra G, Sierakowska H, Carestia C, Fucharoen S, Summerton J, Weller D, et al. Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA 2000; 97:9591-6. (Pubitemid 30650820)
137. Vacek MM, Ma H, Gemignani F, Lacerra G, Kafri T, Kole R. High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA. Blood 2003; 101:104-11. (Pubitemid 36025895)
138. Brun C, Suter D, Pauli C, Dunant P, Lochmüller H, Burgunder JM, et al. U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping. Cell Mol Life Sci 2003; 60:557-66. (Pubitemid 36459534)
139. De Angelis FG, Sthandier O, Berarducci B, Toso S, Galluzzi G, Ricci E, et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. Proc Natl Acad Sci USA 2002; 99:9456-61.
140. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004; 306:1796-9.
141. Liu S, Asparuhova M, Brondani V, Ziekau I, Klimkait T, Schümperli D. Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A. Nucl Acids Res 2004; 32:3752-9.
142. Asparuhova MB, Marti G, Liu S, Serhan F, Trono D, Schümperli D. Inhibition of HIV-1 multiplication by a modified U7 snRNA inducing Tat and Rev exon skipping. J Gene Med 2007; 9:323-34.
143. Asparuhova MB, Barde I, Trono D, Schranz K, Schümperli D. Development and characterization of a triple combination gene therapy vector inhibiting HIV-1 multiplication. J Gene Med 2008; 10:1059-70.
144. Madocsai C, Lim SR, Geib T, Lam BJ, Hertel KJ. Correction of SMN2 pre-mRNA splicing by antisense U7 small nuclear RNAs. Molecular Therapy 2005; 12:1013-22.
145. Geib T, Hertel KJ. Restoration of Full-Length SMN Promoted by Adenoviral Vectors Expressing RNA Antisense Oligonucleotides Embedded in U7 snRNAs. PLoS ONE 2009; 4:8204.
146. Arning S, Grüter P, Bilbe G, Krämer A. Mammalian splicing factor SF1 is encoded by variant cDNAs and binds to RNA. RNA 1996; 2:794-810. (Pubitemid 26374210)
147. Krämer A. The structure and function of proteins involved in mammalian pre-mRNA splicing. Ann Rev Biochem 1996; 65:367-409. (Pubitemid 26250614)
148. Meyer K, Marquis J, Trub J, Nlend Nlend R, Verp S, Ruepp MD, et al. Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum Mol Genet 2009; 18:546-55.
149. Baughan T, Shababi M, Coady TH, Dickson AM, Tullis GE, Lorson CL. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol Ther 2006; 14:54-62. (Pubitemid 43899482)
150. Puttaraju M, Jamison SF, Mansfield SG, Garcia-Blanco MA, Mitchell LG. Spliceosome-mediated RNA transsplicing as a tool for gene therapy. Nat Biotechnol 1999; 17:246-52. (Pubitemid 29122632)
151. Coady TH, Shababi M, Tullis GE, Lorson CL. Restoration of SMN Function: Delivery of a Transsplicing RNA Re-directs SMN2 Pre-mRNA Splicing. Mol Ther 2007; 15:1471-8. (Pubitemid 47099304)
152. Mazarakis ND, Azzouz M, Rohll JB, Ellard FM, Wilkes FJ, Olsen AL, et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 2001; 10:2109-21. (Pubitemid 32998823)
153. Azzouz M, Le T, Ralph GS, Walmsley L, Monani UR, Lee DC, et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 2004; 114:1726-31.
154. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27:59-65.
155. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, et al. Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor Neurons. Mol Ther 2009.